US3080287A - Analgesic compositions - Google Patents

Analgesic compositions Download PDF

Info

Publication number
US3080287A
US3080287A US676392A US67639257A US3080287A US 3080287 A US3080287 A US 3080287A US 676392 A US676392 A US 676392A US 67639257 A US67639257 A US 67639257A US 3080287 A US3080287 A US 3080287A
Authority
US
United States
Prior art keywords
parts
hexobarbital
barbituric acid
compositions
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US676392A
Inventor
Lewenstein Mozes Juda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US676392A priority Critical patent/US3080287A/en
Application granted granted Critical
Publication of US3080287A publication Critical patent/US3080287A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof

Definitions

  • Combinations of analgesics with barbituric acid compounds have been suggested previously.
  • the purpose of such combinations was not only to relieve pain, but also to simultaneously calm down nervous patients by the action of thereapeutic doses of the barbituric acid ingredient in the combinations.
  • the use of such doses renders these compositions less suitable for daytime administration to patients who have to attend their work or other activities, since therapeutic doses of most barbiturates tend to induce sleep and make the patients drowsy.
  • Another disadvantage of such compositions is the cumulative effect of repeated therapeutic doses of ba-rbituric acid compounds when the compositions have to be repeatedly administered during a protracted period of time.
  • compositions in which the mild analgesics and the barbituric acid compounds described hereinafter are combined with each other under the conditions of the present invention are combined with each other under the conditions of the present invention.
  • compositions embodying this invention drowsiness and hangover and other undesirable side-effects occurring in the use of known compositions, are usually not encountered.
  • Example 1 A mixture is prepared from the following ingredients:
  • Example 2 Mixtures are prepared from the ingredients named in 3,080,287 Patented Mar. 5, 1963 the above Example 1, whereby the individual ingredients are used in the following ranges:
  • Example 4 In any of the above Examples 1-3, an equal part by weight of thiamylal sodium or three times in weight doses of thiopental can be substituted for the hexobarbital. A mixture of these barbiturates can also be used. Furthermore, instead of the respective barbituric acid a therapeutically applicable salt thereof, e.g. the sodium salt, can be used and instead of caffeine an equivalent amount of a therapeutically applicable caffeine salt, can be used.
  • a therapeutically applicable salt thereof e.g. the sodium salt
  • caffeine an equivalent amount of a therapeutically applicable caffeine salt
  • the above named in gredients i.e. aspirin, phenacetin, caffeine are used in the usual therapeutic doses, while a barbituric acid compound which is rapid on onset and short in duration, is used in sub-therapeutic doses.
  • a substantially increased synergistic analgesic effect results, which cannot be obtained in the absence of ingredients and proportions called for by the present invention.
  • composition according to the above Example 1 yields a considerably increased analgesic effect in comparison with a similar composition, in which the phenacetin is omitted or substituted by aspirin, or in which the aspirin is omitted or substituted by phenacetin, or in which the conditions called for by the present invention are not observed in other respects.
  • Analgesic compositions containing as active ingredients (a) -390 parts of acetyl salicylic acid; (b) 65-260 parts of acetophenetidine; (0) 16-65 parts of a compound selected from the group consisting of caffeine and therapeutically applicable salts thereof; and at least one compound selected from the group consisting of hexobarbital, thioamylal, thiopental, analogous barbituric acid compounds rapid on onset and short in duration, and therapeutically applicable salts of these compounds, the hexobarbital being used in an amount of 20-60 parts and thioamylal, thiopental and said analogous barbituric acid 3 compounds, being used in amounts equivalent to 20-60 parts of hexobarbital.
  • Analgesic compositions containing as active ingredients (a) aspirin, (b) acetophenetidine, (c) caffeine and (d) hexobarbital, in the proportions of (a) 3 /2 grains (1)) 2% grains (0) /2 grain and (d) 50 milligrams.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

United States Patent 3,080,287 ANALGESIC COMPOSITIONS Mozes Juda Lewenstein, 83-75 116th St, Kew Gardens, N.Y. No Drawing. Filed Aug. 5, 1957, Ser. No. 676,392 2 Claims. (Cl. 167-65) This invention relates to analgesic compositions and it has particular relation to compositions in which analgesic compounds of the type described hereinafter are used in combination with a barbituric acid compound of the type disclosed and under the conditions described hereinafter.
Combinations of analgesics with barbituric acid compounds have been suggested previously. The purpose of such combinations was not only to relieve pain, but also to simultaneously calm down nervous patients by the action of thereapeutic doses of the barbituric acid ingredient in the combinations. The use of such doses renders these compositions less suitable for daytime administration to patients who have to attend their work or other activities, since therapeutic doses of most barbiturates tend to induce sleep and make the patients drowsy. Another disadvantage of such compositions is the cumulative effect of repeated therapeutic doses of ba-rbituric acid compounds when the compositions have to be repeatedly administered during a protracted period of time.
The use of mild analgesics, such as aminopyrine or aspirin, in combination with barbiturates has also been suggested, but the results were not encouraging, because it has been found that little additional analgesia was conferred by barbiturates in combination with such mild analgesics, neither were other advantages obtained.
It has now unexpectedly been discovered that improved analgesic effects can be obtained by compositions in which the mild analgesics and the barbituric acid compounds described hereinafter are combined with each other under the conditions of the present invention.
According to the present invention it has been found that by using a therapeutic dose of (a) aspirin (acetyl salicylic acid) in combination with (b) phenacetin (acetophenetidine), (c) caffeine and (d) with a sub-therapeutic dose of a barbituric acid compound, which is rapid on onset and short in duration of its effect, composiitons are obtained in which the analgesic effect of the active ingredients is accelerated, increased and prolonged in comparison with the added effects of the individual ingredients, as well as in comparison with partial combinations, e.g. (a), (c) and (d) or (b), (c) and (d), and which are practically free from undesired side-effects. In other words, this increase and improvement of the effect requires the co-action of the ingredients (a), (b), (c) and (d) and represents a novel and unexpected synergistic effect of these ingredients.
In the use of compositions embodying this invention drowsiness and hangover and other undesirable side-effects occurring in the use of known compositions, are usually not encountered.
Example 1 A mixture is prepared from the following ingredients:
(a) Aspirin grains 3 /2 (11) Phenacetin do 2% (c) Caffeine do (d) Hexobarbital milligrams 50 The above ingredients are incorporated in conventional manner in each table for oral administration.
Example 2 Mixtures are prepared from the ingredients named in 3,080,287 Patented Mar. 5, 1963 the above Example 1, whereby the individual ingredients are used in the following ranges:
Aspirin grains 2- 6 Phenacetin do 1- 4 Caffeine do A- 1 Hexobarbital milligrams 20-60 The resulting mixtures are formed to tablets in conventional manner.
Example 4 In any of the above Examples 1-3, an equal part by weight of thiamylal sodium or three times in weight doses of thiopental can be substituted for the hexobarbital. A mixture of these barbiturates can also be used. Furthermore, instead of the respective barbituric acid a therapeutically applicable salt thereof, e.g. the sodium salt, can be used and instead of caffeine an equivalent amount of a therapeutically applicable caffeine salt, can be used.
According to the present invention the above named in gredients, i.e. aspirin, phenacetin, caffeine are used in the usual therapeutic doses, while a barbituric acid compound which is rapid on onset and short in duration, is used in sub-therapeutic doses. In the above described proportions, due to co-action of these ingredients a substantially increased synergistic analgesic effect results, which cannot be obtained in the absence of ingredients and proportions called for by the present invention. Thus, for example the composition according to the above Example 1 yields a considerably increased analgesic effect in comparison with a similar composition, in which the phenacetin is omitted or substituted by aspirin, or in which the aspirin is omitted or substituted by phenacetin, or in which the conditions called for by the present invention are not observed in other respects.
The term rapid on onset and short in duration is used in the present application to denote barbituric acid compounds, the therapeutic action of which is analogous to that of the compounds described in the above Examples.
The parts mentioned above are parts by weight if not otherwise stated.
What is claimed is:
1. Analgesic compositions containing as active ingredients (a) -390 parts of acetyl salicylic acid; (b) 65-260 parts of acetophenetidine; (0) 16-65 parts of a compound selected from the group consisting of caffeine and therapeutically applicable salts thereof; and at least one compound selected from the group consisting of hexobarbital, thioamylal, thiopental, analogous barbituric acid compounds rapid on onset and short in duration, and therapeutically applicable salts of these compounds, the hexobarbital being used in an amount of 20-60 parts and thioamylal, thiopental and said analogous barbituric acid 3 compounds, being used in amounts equivalent to 20-60 parts of hexobarbital.
2. Analgesic compositions containing as active ingredients (a) aspirin, (b) acetophenetidine, (c) caffeine and (d) hexobarbital, in the proportions of (a) 3 /2 grains (1)) 2% grains (0) /2 grain and (d) 50 milligrams.
References Cited in the file of this patent Goodman et 211.: Pharmacological Basis of Therapeutics, 2nd ed., (1955), Macmillan Co., N.Y., pp 125, 127, 138 and 141.
Friedman et al.: J.A.M.A., vol. 163, No. 13, Mar. 30, 1957, pp. 11114117.
Orkin et al.: Survey of Anesthesiology, October 1957, pp. 460-464.
Batterman: I.A.M.A., vol. 155, No. 11, July 10, 1954, pp. 965-968.
Beecher: J.A.M.A., vol. 158, No. 5, June 4, 1955, pp. 399-401.
J.A.M.A., vol. 165, N0. 9, Nov. 2, 1957, pp. 1172- 1173.

Claims (1)

1. ANALGESIC COMPOSITIONS CONTAINING AS ACTIVE INGREDIENTS (A) 130-390 PARTS OF ACETYL SALICYLIC ACID; (B) 65-260 PARTS OF ACETOPHENETIDINE; (C) 16-65 PARTS OF A COMPOUND SELECTED FROM THE GROUP CONSISTING OF CAFFEINE AND THERAPEUTICALLY APPLICABLE SALTS THEREOF; AND AT LEAST ONE COMPOUND SELECTED FROM THE GROUP CONSISTING OF HEXOBARBITAL, THIOMYLAL, THIPPENTAL, ANALOGOUS BARBITURIC ACID COMPOUNDS RAPID ON ONSET AND SHORT IN DURATION, AND THERAPEUTICALLY APPLICABLE SALTS OF THESE COMPOUNDS, THE HEXOBARBITAL BEING USED IN AN AMOUNT OF 20-60 PARTS AND THIOAMYLAL, THIOPENTAL AND SAID ANALOGOUS BARBITURIC ACID COMPOUNDS, BEING USED IN AMOUNTS EQUIVALENT TO 20-60 PARTS OF HEXOBARBITAL.
US676392A 1957-08-05 1957-08-05 Analgesic compositions Expired - Lifetime US3080287A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US676392A US3080287A (en) 1957-08-05 1957-08-05 Analgesic compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US676392A US3080287A (en) 1957-08-05 1957-08-05 Analgesic compositions

Publications (1)

Publication Number Publication Date
US3080287A true US3080287A (en) 1963-03-05

Family

ID=24714320

Family Applications (1)

Application Number Title Priority Date Filing Date
US676392A Expired - Lifetime US3080287A (en) 1957-08-05 1957-08-05 Analgesic compositions

Country Status (1)

Country Link
US (1) US3080287A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3218233A (en) * 1963-01-24 1965-11-16 Lewenstein Mozes Juda Analgesic compositions
US3274203A (en) * 1963-05-31 1966-09-20 Du Pont 1-carbamyl and thiocarbamyl-3-amino-4-nonsubstituted and substituted pyrazoles
US3320262A (en) * 1964-09-22 1967-05-16 Lewenstein 14 hydroxy morphine and codeine carboxymethyloximes
US3331828A (en) * 1964-09-30 1967-07-18 Merck & Co Inc Isolation of gamma-l-glutamyl dipeptides from glutamic acid fermentation broths by ion exchange
US4505862A (en) * 1981-04-14 1985-03-19 Bristol-Myers Company Diphenydramine dihydrogencitrate
US4880791A (en) * 1984-07-21 1989-11-14 Hoechst Aktiengesellschaft Combination product composed of xanthine derivatives and O-acetylsalicylic acid or its pharmacologically tolerated salts, and its use
US5055460A (en) * 1990-04-26 1991-10-08 Mitchell Friedlander Method for weight loss
US5972916A (en) * 1997-07-14 1999-10-26 Bristol-Myers Squibb Company Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
US6642243B1 (en) 1999-07-22 2003-11-04 Ashkan Imanzahrai Migraine medicine and method for treating same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3218233A (en) * 1963-01-24 1965-11-16 Lewenstein Mozes Juda Analgesic compositions
US3274203A (en) * 1963-05-31 1966-09-20 Du Pont 1-carbamyl and thiocarbamyl-3-amino-4-nonsubstituted and substituted pyrazoles
US3277100A (en) * 1963-05-31 1966-10-04 Du Pont Novel substituted pyrazoles
US3320262A (en) * 1964-09-22 1967-05-16 Lewenstein 14 hydroxy morphine and codeine carboxymethyloximes
US3331828A (en) * 1964-09-30 1967-07-18 Merck & Co Inc Isolation of gamma-l-glutamyl dipeptides from glutamic acid fermentation broths by ion exchange
US4505862A (en) * 1981-04-14 1985-03-19 Bristol-Myers Company Diphenydramine dihydrogencitrate
US4880791A (en) * 1984-07-21 1989-11-14 Hoechst Aktiengesellschaft Combination product composed of xanthine derivatives and O-acetylsalicylic acid or its pharmacologically tolerated salts, and its use
US5055460A (en) * 1990-04-26 1991-10-08 Mitchell Friedlander Method for weight loss
US5972916A (en) * 1997-07-14 1999-10-26 Bristol-Myers Squibb Company Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
US6642243B1 (en) 1999-07-22 2003-11-04 Ashkan Imanzahrai Migraine medicine and method for treating same

Similar Documents

Publication Publication Date Title
DE3586545T2 (en) INCREASED PAINLESSNESS EFFECTIVE PHARMACEUTICAL COMPOSITIONS.
HU178867B (en) Process for preparing synergetic analgetic composition containing nalbuphine and acetaminophene
JPS60214733A (en) Pharmaceutical product rendering improved analgesia
US3080287A (en) Analgesic compositions
EP0185210B1 (en) Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis
WO1992000743A1 (en) Use of taurolidine and/or taurultam for the treatment of tumours
US3439094A (en) Analgesic compositions containing namol xenyrate,caffeine and acetyl-rho-aminophenol
US3312593A (en) Anti-inflammatory compositions of aspirin and niacin
US3019165A (en) Sunburn preventive and burn remedy
US3218233A (en) Analgesic compositions
DE69814089T2 (en) USE OF A DRAFLAZINE ANALOGUE FOR TREATMENT
US3995058A (en) Treatment of ethanol withdrawal symptoms with levodopa
US4017614A (en) Compositions for the relief of migraine
DE3525390C2 (en)
DE60128472T2 (en) COMBINED TUMOR THERAPY BASED ON DISTAMYCIN ACRYLOYL DERIVATIVES AND ALKYLATIVES
US4534974A (en) Pharmaceutical compositions with codeine
US3197370A (en) Pyrilamine tannate compositions
EP0340540B1 (en) Agent for the prophylaxis of a heart infarct and for the prevention of another infarct
US4575506A (en) Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics
WO2007115997A2 (en) Combination preparations from modafinil, ritalin and topiramat for use in cocaine dependency and/or for treating impulse control disorders
DE3247514C2 (en)
US3129137A (en) Method of inhibiting gastro-intestinal irritation
US3422195A (en) Antihistaminic and motion sickness preventing compositions
Winsor et al. Monoamine oxidase inhibitors and angina pectoris
DE60312215T2 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN LTB4 INHIBITOR AND A COX-2 INHIBITOR OR A COMBINED COX1 / 2 INHIBITOR